Adjuvant therapy in resected non-small cell lung cancer: current status and perspectives
Abstract Adjuvant chemotherapy increases overall survival of patients with completely resected non-small cell lung cancer. Adjuvant therapy with immune checkpoint inhibitors and tyrosine kinase inhibitors have further improved outcome in selected patients. These therapeutic achievements are discussed in the present commentary.
Authors
- Robert Pirker (ORCID: https://orcid.org/0000-0003-4457-7752)
Institutions
- Central European Cooperative Oncology Group (AT)
Publication Details
- Journal
- Holistic Integrative Oncology
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1007/s44178-024-00136-2
- Citations
- 2
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04